MannKind is trading at $3.97, up 6.97%, with no company-specific announcement identified as a catalyst.
- No new MannKind-specific announcement was identified for November 4.
- The move coincides with a broader biotech rally, with XBI up 2.13%, and gains in major market indexes.
- MannKind’s Q3 results are scheduled for November 5 after market close. The report may be drawing investor attention, but there is no evidence it caused the move.